Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.58 |
| ▸ | SLC6A3 | Q01959 | 7/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8907832 | 0.87 | SLC6A2 (0.56) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL15719671 | 0.83 | SLC6A4 (0.58) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL30330305 | 0.83 | CYP2D6 (0.62) | SLC6A4SLC6A2SLC6A3CYP2D6TACR1 | |
| SCHEMBL23293452 | 0.83 | SLC6A4 (0.60) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL14035499 | 0.83 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL5139722 | 0.83 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL28981205 | 0.83 | TP53 (0.52) | SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL30331028 | 0.83 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| Hydrochloric Acid SCHEMBL17107316 | 0.82 | SLC6A4 (0.57) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 | |
| SCHEMBL27791354 | 0.81 | SLC6A4 (0.50) | SLC6A4SLC6A2SLC6A3KCNH2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-09 | — | — | US | disclosed |
| CN-112585139-B | Naphthyridinone compounds as T cell activators | 百时美施贵宝公司 | 2023-12-01 | — | — | CN | disclosed |
| EP-3814347-B1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-05-03 | — | — | EP | disclosed |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2023-04-20 | — | — | US | disclosed |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2021-09-09 | — | — | US | disclosed |
| CN-112585139-A | Nalidinone compounds as T cell activators | 百时美施贵宝公司 | 2021-03-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866430-B2 | Naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | SLC6A4 4861/4885SLC6A2 4780/4885SLC6A3 4364/4885 |
| US-20230117324-A1 | OXAZINE MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS | MGLL, LPL, LIPC | SLC6A4 4841/4885SLC6A2 4783/4885SLC6A3 4431/4885 |
| US-20210277004-A1 | NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | SLC6A4 4861/4885SLC6A2 4780/4885SLC6A3 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.